Seeking approval: For new drugs and devices, a faster track to market often found in Europe

Lee, Jaimy
July 2011
Modern Healthcare;7/25/2011, Vol. 41 Issue 30, p30
Trade Publication
The article discusses why drug companies and medical device manufacturers in the U.S. are focusing to market in Europe. According to Delcath President and chief executive officer (CEO) Eamonn Hobbs, there is a difficult regulatory environment in the U.S., making it difficult to bring new drug and device technologies. A report from California Healthcare Institute and the Boston Consulting Group has found that by 2007, new drugs were approved two months faster in the European Union, in comparison to the U.S.


Related Articles

  • Quantifying The Food And Drug Administration's Rulemaking Delays Highlights The Need For Transparency. Hwang, Thomas J.; Avorn, Jerry; Carpenter, Daniel; Kesselheim, Aaron S. // Health Affairs;Feb2014, Vol. 33 Issue 2, p309 

    The article presents a study on the U.S. Food and Drug Administration's (FDA) rulemaking process by examining the evolution of significant rules that the agency published during 2000-2012 for drugs, devices and other medical products. It believes that the FDA's rulemaking is controversial due to...

  • Industry Pipeline.  // Ocular Surgery News;5/25/2014, Vol. 32 Issue 10, p30 

    This section offers news briefs on ocular surgery as of May 2014. It announces the U.S. Food and Drug Administration's (FDA) approval of the application from Hi-Tech Pharmacal for once-daily bromfenac ophthalmic solution 0.09 percent. Also reported are the 510(k) clearance received by Bausch +...

  • The missing link: What technologies are lacking for US premium surgeons. Jackson, Mitchell A. // Ocular Surgery News;4/10/2014, Vol. 32 Issue 7, p36 

    The author comments on the apparent gap between the U.S. regulatory approval process of surgical and pharmaceutical products and that of the rest of the world. Topics covered include the need for the U.S. regulatory process to revise its approach, the focus of regulatory process on safety, and...

  • Ophthalmic innovations affected by FDA, Patient Protection and Affordable Care Act. Biro, Ashley // Ocular Surgery News;1/25/2013, Vol. 31 Issue 2, p40 

    The article presents various views of leaders about business, and regulatory issues of Food and Drug Administration at the Ophthalmology Innovation Summit. Jim Mazzo, president of Abbott medical Optics said that increasing disruption is causing by FDA delays. Richard Lindstrom, MD OSN Chief...

  • Venture capital community vital to advances in ophthalmology. Lindstrom, Richard L. // Ocular Surgery News;4/25/2011, Vol. 29 Issue 8, p3 

    The author discusses the significance of venture capital community to medical innovation in ophthalmology. He states that the venture capital-supported startup companies were found by large strategic companies as the most economically viable pipeline for new product development. He says that the...

  • When considering new technology, think about the three stakeholders.  // Ocular Surgery News;10/25/2014, Vol. 32 Issue 20, p30 

    The author stresses the need for people involved in the field of ophthalmology to think about the three stakeholders, namely the medical drug and device industry, the physician practice, and the patient, when considering new technologies, like presbyopia-correcting intraocular lenses (IOLs).

  • Voters, candidates at odds on healthcare. Muchmore, Shannon // Modern Healthcare;8/24/2015, Vol. 45 Issue 34, p0008 

    The article discusses campaign strategies of U.S. Republican and Wisconsin Governor Scott Walker for the 2016 Presidential election, citing involvement of healthcare issues in his campaign. It states that Walker has introduced the Day One Patient Freedom Plan as a proposed alternative to the...

  • China's 2011 GMP Regulations-Combatting Poor API/Drug Quality. Anisfeld, Michael H. // Journal of GXP Compliance;Feb2013, Vol. 17 Issue 1, p1 

    The article reports that China manufactures about 80 percent of active pharmaceutical ingredients (APIs) imported into the U.S. for use in manufacturing finished dosage forms. Particular focus is given to the efforts of the U.S. Food and Drug Administration (FDA) in conducting good manufacturing...

  • Industry Pipeline.  // Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p60 

    The article focuses on premarket approvals of the U.S. Food and Drug Administration (FDA) including one for MA09-hRPE cell orphan drug status given to Advanced Cell Technology, one for the Zymaxid topical anti-infective flouroquinolone from Allergan, and one for Sun Pharma's market application.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics